Related Experiment Video
Updated: Feb 14, 2026

Open Tracheostomy Gastric Acid Aspiration Murine Model of Acute Lung Injury Results in Maximal Acute Nonlethal Lung Injury
Published on: February 26, 2017
Remimazolam alleviates acute lung injury by inhibiting ferroptosis: a multi-omics system pharmacology approach with
Ruohan Li1, Lingzhi Qin1, Jiajia Ren1
1Department of Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi 5 Lu, Xi'an, 710004, Shaanxi, PR China.
Background:
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe clinical conditions with significant global health burdens. Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, has been implicated in the pathogenesis of ALI/ARDS. Remimazolam (REM), an ultra-short-acting benzodiazepine sedative, has shown therapeutic potential in ALI/ARDS; however, whether its protective effects are mediated by ferroptosis modulation remains unclear.
Methods:
The anti-injury efficacy of REM was first assessed in LPS induced ALI mice. To investigate the molecular mechanisms underlying the protective effects of REM in ALI/ARDS, an integrated multi-omics approach was employed. Potential targets of REM and ALI/ARDS were systematically identified through pharmacophore-based screening. Publicly available RNA-sequencing (RNA-seq) data (GSE5883) from lipopolysaccharide (LPS)-stimulated human pulmonary microvascular endothelial cells was retrieved from the GEO data sets. Network pharmacology and transcriptomic analyses were employed to elucidate ferroptosis-related pathways potentially modulated by REM in LPS-induced ALI mice. Subsequent in vivo (ALI mice) and in vitro (MLE-12 cell) experimental validation was performed, wherein ferroptosis-related markers, including iron content, malondialdehyde (MDA), the ratio of reduced to oxidized glutathione (GSH/GSSG), cyclooxygenase-2 (COX2), solute carrier family 7 member 11 (SLC7A11), glutathione peroxidase 4 (GPX4), and heme oxygenase-1 (HO-1), were assessed. To further validate REM's HO-1-dependent anti-ferroptotic effects, we treated MLE-12 cells with an HO-1 inhibitor and assessed ferroptosis biomarkers.
Results:
REM treatment reduced pathological lung injury in ALI mice. Network pharmacology analysis revealed that REM's potential targets in ALI/ARDS were enriched in biological processes related to inflammation, oxidative stress, metal ion response, and fatty acid metabolism. RNA-seq analysis further confirmed that REM modulated genes associated with metal ion regulation, lipid metabolism, and oxidative stress. In vivo, REM significantly decreased LPS-induced pulmonary iron overload and MDA levels while simultaneously restoring the GSH/GSSG ratio. Furthermore, REM suppressed LPS-induced upregulation of COX2 and reversed downregulation of SLC7A11 and GPX4. Notably, HO-1 expression was significantly increased in the lung tissues of REM-treated ALI mice compared with ALI mice. In MLE-12 cells, LPS downregulated GPX4, an effect reversed by REM; HO-1 inhibition partially abrogated REM's protection.
Conclusions:
This study demonstrated that REM alleviated LPS-induced lung injury by inhibiting ferroptosis, potentially through upregulation of HO-1 and restoration of the SLC7A11-GSH-GPX4 axis. These findings provide novel mechanistic insights into the anti-ferroptotic effects of REM and highlight its therapeutic potential in ALI/ARDS management.
Insights
Remimazolam alleviates acute lung injury by inhibiting ferroptosis, a cell death pathway. This study reveals its protective effects are linked to heme oxygenase-1 (HO-1) and the SLC7A11-GSH-GPX4 axis, suggesting therapeutic potential.
Area of Science:
- Biomedical Science
- Pharmacology
- Cell Biology
Background:
- Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) pose significant global health challenges.
- Ferroptosis, a form of iron-dependent cell death involving lipid peroxidation, is implicated in ALI/ARDS pathogenesis.
- Remimazolam (REM), an ultra-short-acting sedative, shows promise for ALI/ARDS, but its ferroptosis-modulating effects are unknown.
Purpose of the Study:
- To investigate the anti-injury efficacy of Remimazolam (REM) in lipopolysaccharide (LPS)-induced acute lung injury (ALI).
- To elucidate the molecular mechanisms underlying REM's protective effects, particularly its role in ferroptosis modulation.
- To validate the therapeutic potential of REM in ALI/ARDS management.
Main Methods:
- Assessed REM's efficacy in LPS-induced ALI mice and utilized an integrated multi-omics approach.
- Employed network pharmacology and transcriptomic analysis of RNA-seq data (GSE5883) to identify REM targets and pathways.
- Validated findings in vivo (ALI mice) and in vitro (MLE-12 cells), assessing ferroptosis markers (iron, MDA, GSH/GSSG, COX2, SLC7A11, GPX4, HO-1).
Main Results:
- REM treatment reduced lung injury in ALI mice, decreasing pulmonary iron overload and MDA levels while restoring GSH/GSSG ratio.
- REM modulated genes involved in metal ion regulation, lipid metabolism, and oxidative stress, suppressing COX2 and reversing SLC7A11/GPX4 downregulation.
- REM increased HO-1 expression in ALI mouse lungs; in MLE-12 cells, REM reversed GPX4 downregulation, an effect partially blocked by HO-1 inhibition.
Conclusions:
- Remimazolam alleviates LPS-induced lung injury by inhibiting ferroptosis.
- REM's protective effects may involve upregulation of HO-1 and restoration of the SLC7A11-GSH-GPX4 axis.
- These findings highlight REM's therapeutic potential for ALI/ARDS by providing mechanistic insights into its anti-ferroptotic actions.
More Related Videos
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
08:58Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Related Concept Videos
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Reliability and Validity
Feedback Inhibition